New studies presented at the 43rd international society for heart and lung transplant validate the applicability of the bva-100® blood test for patients with advanced heart failure

Study demonstrates bva provides more accurate congestion measurement in challenging patient populations oak ridge, tn, april 20, 2023 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, today announces new data from duke university medical center validating the benefits of the company's bva-100 blood test in optimizing individualized therapy for advanced heart failure patients. data were presented at the 43rd international society for heart and lung transplant (ishlt) annual meeting and scientific sessions, which brought together the world's leading experts in heart and lung transplant held at the colorado convention center, from april 19-22, in denver, co.
DXR Ratings Summary
DXR Quant Ranking